Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Resistance Exercise as an Intervention in Type 2 Diabetes Mellitus
The main purpose of this study is to assess the impact of exercise training (aerobic exercise, resistance exercise, combined aerobic and resistance exercise) versus a sedentary waiting list control on glycemic control (as reflected in reduced hemoglobin A1c [HbA1c]), body composition (weight, body mass index [BMI], waist circumference, total body fat, visceral and subcutaneous abdominal fat, mid-thigh muscle cross-sectional area), lipids (Apo-B, Apo-A1, Apo-B/A1 ratio, low density lipoprotein (LDL) particle diameter, high-sensitivity C-reactive protein) and quality of life.
Background. The incidence of type 2 diabetes mellitus in the Western world is rising rapidly
due to increases in obesity and sedentary behaviour, and diabetes is among the most potent
common risk factors for premature disability and mortality. Landmark clinical trials such as
the UK Prospective Diabetes Study proved that these excess risks in type 2 diabetes can be
reduced through relatively modest improvements in glycemic control (HbA1c difference of 0.9%
over time). The excess morbidity and mortality in diabetes is attributable both to
hyperglycemia and to a cluster of other metabolic disturbances associated with insulin
resistance, and exercise can have beneficial effects on all of these abnormalities. The
standard recommendation to people with diabetes has been to perform aerobic exercise such as
brisk walking, swimming, or jogging. There is very little research on resistance exercise
(such as weight lifting or exercise with weight machines) in type 2 diabetes. Resistance
exercise in non-diabetic subjects increases lean body mass, resulting in increased metabolic
rate, decreased insulin resistance and increased glucose disposal. Furthermore, in a recent
randomized trial the addition of resistance exercise to a cardiac rehabilitation program
resulted in marked improvements in quality of life, to a far greater extent than seen with
aerobic exercise alone. For these reasons, we feel that resistance exercise in type 2
diabetes is a modality worthy of further research. A pilot study of our present proposal,
funded by the Canadian Diabetes Association (CDA) is in progress; compliance has been
excellent with >90% attendance.
Primary research question: In patients with type 2 diabetes, does a 6-month resistance or
aerobic training program result in improved glycemic control as reflected in reduced
hemoglobin A1c (HbA1c)? Is the effect of one type of exercise additive to that of the other?
Secondary research questions: In patients with type 2 diabetes, what are the effects of each
exercise modality on:
1. Body composition (assessed using gold-standard methods including CT scan and deuterium
oxide), resting energy expenditure (using indirect calorimetry) and insulin resistance?
To what extent do changes in these parameters mediate changes in HbA1c?
2. Important nontraditional metabolic CHD risk factors (LDL particle diameter, plasma
insulin, apoprotein B, c-reactive protein, free fatty acids) and traditional metabolic
CHD risk factors (HDL-C, LDL-C, triglycerides, total/HDL cholesterol ratio, BP)?
3. Health-related quality of life (QOL) as measured by the Well-Being questionnaire or the
SF-36? Does modality of exercise or change in quality of life from baseline to 6 months
predict frequency of exercise during the 6 months following the intervention?
Study design: Randomized controlled trial. After a 4-week supervised low-intensity exercise
run-in period to test compliance, previously inactive Type 2 diabetic subjects not currently
engaging in regular exercise are randomized to 4 arms: aerobic exercise 3X per week,
resistance exercise 3X per week, both combined or waiting-list control. The exercise
intervention takes place at YMCA branches in metropolitan Ottawa. Exercise is closely
supervised and progressive in intensity and duration. Compliance is verified through direct
supervision, completion of detailed exercise logs, and central automated electronic tracking
of YMCA attendance through scanning of membership cards. Primary outcomes are measured at 6
months. At the end of 6 months subjects are given a maintenance program and reexamined 6
months later to assess the durability of any benefits from the exercise program. During the
6 month intervention period diet is standardized using repeated sessions with a dietitian,
and doses of medications altering glucose, lipids and BP are held constant unless change is
medically urgent.
Significance: The global burden of type 2 diabetes is increasing, and complications of the
illness occur primarily in those whose glycemic control is fair or poor. If appropriately
selected exercise training improves glycemic control and is adopted by more patients, it is
likely that the morbidity associated with type 2 diabetes will be decreased. This is
particularly true if such training also improves quality of life, and more people are thus
inclined to continue exercising in the long term.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |